Sartorius Stedim Biotech S.A. (SRTOY) Stock Price & Analysis
Sartorius Stedim Biotech S.A. (SRTOY) — price $24.44 (-1.37%), as of the Nov 19, 2026 trading session; market cap $23.8B.
Educational signal · not a buy or sell recommendation · How to read this
Sartorius Stedim Biotech S.A. · SRTOY · Healthcare · Medical - Instruments & Supplies
Sartorius Stedim Biotech S.A. operates globally, providing essential instruments and consumables to the biopharmaceutical industry. Their product range is extensive, featuring items such as cell lines, cell culture growth media, and bioreactors.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $24.44 | |
| Change on the day | -1.37% | |
| 52-week range | $17.25–$26.54 | |
| Market capitalisation | $23.8B | — |
| Price / earnings (trailing) | 67.13 | |
| Shares traded on the day | 1.6K | |
| Beta (volatility vs the S&P 500) | 1.14 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Sartorius Stedim Biotech (SRTOY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 24, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: May 2, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On May 2, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Sartorius Stedim Biotech (SRTOY), and what does it report?
Short answer
Sartorius Stedim Biotech S.A. operates globally, providing essential instruments and consumables to the biopharmaceutical industry. Their product range is extensive, featuring items such as cell lines, cell culture growth media, and bioreactors. Healthcare / Medical Instruments & Supplies Headquarters: Zone Industrielle Les Paluds, Aubagne, PAC, 13781, FR. It employs 10,265 people and is led by Rene Faber. In Q3 FY2026 it reported revenue of €758M and net income of €95M. The market values it at $23.8B.
What do the latest results show for Sartorius Stedim Biotech (SRTOY)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of €758M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | €758M | €95M | €0.01 (diluted) |
| Q2 FY2026 | €778M | €95M | €0.01 (diluted) |
| Q1 FY2026 | €774M | €90M | €0.01 (diluted) |
| Q4 FY2025 | €765M | €37M | €0.0048 (diluted) |
What are the financial strengths and risks for Sartorius Stedim Biotech (SRTOY)?
Short answer · as of
The distress and quality screens read Altman Z 36.64 · Piotroski F 7. Trailing ratios: ROE 7.7% · ROA 4.0% · current ratio 1.22 · earnings yield 1.5% · free-cash-flow yield 1.2%.
How is Sartorius Stedim Biotech scored?
Research dated 2026-09-12.
Compared with a conventional laboratory-instrument vendor, Sartorius Stedim participates in much more of the customer’s production chain. Its portfolio connects cell lines and media with bioreactors, separation, purification, fluid management, secure storage and workflow analytics.
That breadth ties demand to biopharmaceutical development and manufacturing activity rather than isolated equipment replacement. The useful comparison is therefore the balance among equipment, consumables, services and software, not healthcare-instrument valuation multiples alone.
| Company | Price | Market value | Score |
|---|---|---|---|
| $189.90 Sep 25, 2026 | $294B | — Model unavailable | |
| $195.80 Nov 19, 2026 | $89.8B | — Model unavailable | |
| $14.29 Nov 19, 2026 | $32.2B | — Model unavailable | |
| $39.50 Nov 19, 2026 | $174B | — Model unavailable | |
| $404.02 Nov 18, 2026 | $28.1B | — 5-pillar · not comparable | |
| $242.61 Nov 18, 2026 | $34.1B | — 5-pillar · not comparable | |
| $74.52 Nov 19, 2026 | $35.8B | — 5-pillar · not comparable | |
| $25.39 Nov 19, 2026 | $13.1B | — 5-pillar · not comparable | |
| $60.33 Nov 19, 2026 | $11.5B | — 5-pillar · not comparable | |
| $37.84 Nov 19, 2026 | $49.8B | — 5-pillar · not comparable | |
| $170.29 Nov 19, 2026 | $10.9B | — 5-pillar · not comparable | |
| $15.37 Nov 18, 2026 | $10.4B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held SRTOY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported SRTOY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Sartorius Stedim Biotech (SRTOY)?
Sartorius Stedim Biotech Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.
What makes Sartorius Stedim more than a medical-instruments supplier?
Its products span the bioprocess itself, from cell cultivation and fermentation through filtration, purification, storage and transport. Services and analytics software extend that role beyond selling laboratory hardware.
Why do cell and gene therapy kits matter to Sartorius Stedim?
Presterilized kits and hollow-fiber membrane devices place Sartorius Stedim inside specialized cell and gene therapy processes. They broaden the portfolio from core bioreactors into fluid handling, separation and material transfer.
What is the SRTOY stock price today?
The last price recorded for Sartorius Stedim Biotech S.A. (SRTOY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 18 figures on this page — 15 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com